227 related articles for article (PubMed ID: 37058845)
21. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors.
Prasongtanakij S; Preedagasamzin S; Jittorntrum B; Anurathapan U; Puavilai T; Niparuck P; Chantrathammachart P; Piyajaroenkij T; Uaesoontrachoon K; Uchibori R; Ozawa K; Ohmine K; Hongeng S
Eur J Haematol; 2024 Feb; 112(2):248-256. PubMed ID: 37222081
[TBL] [Abstract][Full Text] [Related]
23. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
Lee L; Lim WC; Galas-Filipowicz D; Fung K; Taylor J; Patel D; Akbar Z; Alvarez Mediavilla E; Wawrzyniecka P; Shome D; Reijmers RM; Gregg T; Wood L; Day W; Cerec V; Ferrari M; Thomas S; Cordoba S; Onuoha S; Khokhar N; Peddareddigari V; Al-Hajj M; Cavet J; Zweegman S; Rodriguez-Justo M; Youg K; Pule M; Popat R
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399355
[TBL] [Abstract][Full Text] [Related]
24. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
Stock S; Fertig L; Gottschlich A; Dörr J; Märkl F; Majed L; Menkhoff VD; Grünmeier R; Rejeski K; Cordas Dos Santos DM; Theurich S; von Bergwelt-Baildon M; Endres S; Subklewe M; Kobold S
Cancer Immunol Immunother; 2024 Apr; 73(6):100. PubMed ID: 38630291
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
26. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
Sun Y; Yang XN; Yang SS; Lyu YZ; Zhang B; Liu KW; Li N; Cui JC; Huang GX; Liu CL; Xu J; Mi JQ; Chen Z; Fan XH; Chen SJ; Chen S
Signal Transduct Target Ther; 2023 Dec; 8(1):445. PubMed ID: 38062078
[TBL] [Abstract][Full Text] [Related]
27. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY
Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
29. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
30. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
[TBL] [Abstract][Full Text] [Related]
31. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
32. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
33. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Lam N; Trinklein ND; Buelow B; Patterson GH; Ojha N; Kochenderfer JN
Nat Commun; 2020 Jan; 11(1):283. PubMed ID: 31941907
[TBL] [Abstract][Full Text] [Related]
34. All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
García-Guerrero E; Rodríguez-Lobato LG; Sierro-Martínez B; Danhof S; Bates S; Frenz S; Haertle L; Götz R; Sauer M; Rasche L; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Prommersberger SR
Haematologica; 2023 Feb; 108(2):568-580. PubMed ID: 36722406
[TBL] [Abstract][Full Text] [Related]
35. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma.
Larson RC; Kann MC; Graham C; Mount CW; Castano AP; Lee WH; Bouffard AA; Takei HN; Almazan AJ; Scarfó I; Berger TR; Schmidts A; Frigault MJ; Gallagher KME; Maus MV
Nat Commun; 2023 Nov; 14(1):7509. PubMed ID: 37980341
[TBL] [Abstract][Full Text] [Related]
36. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
[TBL] [Abstract][Full Text] [Related]
37. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
38. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
Ouyang W; Jin SW; Xu N; Liu WY; Zhao H; Zhang L; Kang L; Tao Y; Liu Y; Wang Y; Wang J; Liu F; Yu L; Liu Z; Mi JQ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38589248
[TBL] [Abstract][Full Text] [Related]
39. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
40. BCMA CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]